A detailed history of Black Rock Inc. transactions in Passage Bio, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 817,529 shares of PASG stock, worth $531,393. This represents 0.0% of its overall portfolio holdings.

Number of Shares
817,529
Previous 922,547 11.38%
Holding current value
$531,393
Previous $1.25 Million 48.19%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.79 - $1.58 $82,964 - $165,928
-105,018 Reduced 11.38%
817,529 $645,000
Q1 2024

May 10, 2024

SELL
$0.86 - $1.73 $86,013 - $173,027
-100,016 Reduced 9.78%
922,547 $1.25 Million
Q4 2023

Feb 13, 2024

BUY
$0.6 - $1.01 $6,143 - $10,341
10,239 Added 1.01%
1,022,563 $1.03 Million
Q3 2023

Nov 13, 2023

SELL
$0.66 - $1.01 $28,312 - $43,326
-42,898 Reduced 4.07%
1,012,324 $668,000
Q2 2023

Aug 11, 2023

BUY
$0.82 - $1.19 $1,002 - $1,455
1,223 Added 0.12%
1,055,222 $991,000
Q1 2023

May 12, 2023

SELL
$0.96 - $1.88 $66,910 - $131,032
-69,698 Reduced 6.2%
1,053,999 $1.01 Million
Q4 2022

Feb 13, 2023

SELL
$1.06 - $1.48 $233,459 - $325,962
-220,245 Reduced 16.39%
1,123,697 $1.55 Million
Q3 2022

Nov 14, 2022

SELL
$1.22 - $2.48 $29,774 - $60,524
-24,405 Reduced 1.78%
1,343,942 $1.68 Million
Q2 2022

Aug 12, 2022

SELL
$1.63 - $3.46 $3.14 Million - $6.66 Million
-1,924,445 Reduced 58.44%
1,368,347 $3.23 Million
Q1 2022

May 12, 2022

SELL
$2.66 - $6.49 $528,709 - $1.29 Million
-198,763 Reduced 5.69%
3,292,792 $10.2 Million
Q4 2021

Feb 10, 2022

BUY
$6.24 - $10.2 $2.33 Million - $3.81 Million
373,532 Added 11.98%
3,491,555 $22.2 Million
Q3 2021

Nov 09, 2021

BUY
$9.73 - $15.52 $163,152 - $260,239
16,768 Added 0.54%
3,118,023 $31.1 Million
Q2 2021

Aug 11, 2021

BUY
$12.44 - $19.45 $38.6 Million - $60.3 Million
3,101,255 New
3,101,255 $41.1 Million

Others Institutions Holding PASG

About Passage BIO, Inc.


  • Ticker PASG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,463,200
  • Market Cap $35.4M
  • Description
  • Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...
More about PASG
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.